Document is current

Article History

Received: 4 June 2021

Accepted: 24 August 2021

First Online: 7 September 2021

Declarations

:

: Dr. Bevers reports current grants from NIH K23NS112474 and AAN CRTS AI18-0000000062; in addition, Dr. Bevers reports prior grants from Andrew David Heitman Neurovascular fund, and prior grants and personal fees from Biogen, personal fees from Atlas Ventures, and personal fees from Dynamed. Dr. Kimberly reports grants from NIH R01 NS099209 and grants AHA 20SRG35540018 related to the current work; in addition, Dr. Kimberly reports grants and personal fees from Biogen, and grants and personal fees from NControl Therapeutics outside the submitted work; in addition, Dr. Kimberly has a patent to PCT/US2018/018537 pending and licensed. Dr. Sheth reports grants from Biogen, AHA, Hyperfine, NIH, Novartis and Bard. He reports consulting fees from NControl Therapeutics and Zoll, outside the submitted work. He is on a data safety monitoring board for Zoll. He has patents for wearables and nanoparticles, unrelated to the submitted work. Dr. Sheth reports stock options in Alva Health. Dr. Lev reports grants from GE Heathcare and Siemens Healthcare. He reports consulting fees from GE Healthcare and Takea/Roche-Genentech outside the submitted work. He reports patents pending in Electrical Impedance Spectroscopy and machine learning for computed tomography scan lesion detection. All other authors report no disclosures.

: Applicable institutional review board approval was obtained for access to data from all underlying studies and registries used in this study.